Jeff Settleman

UNVERIFIED PROFILE

Are you Jeff Settleman?   Register this Author

Register author

Jeff Settleman

Publications by authors named "Jeff Settleman"

Are you Jeff Settleman?   Register this Author

57Publications

-Reads

Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.

Mol Cancer Ther 2017 Sep 15;16(9):1729-1738. Epub 2017 Jun 15.

Department of Discovery Oncology, Genentech, South San Francisco, California.

View Article
September 2017

Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in mutant mesenchymal-like NSCLC cells.

Sci Signal 2017 Sep 12;10(496). Epub 2017 Sep 12.

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.

View Article
September 2017

A three-drug combination to treat BRAF-mutant cancers.

Nat Med 2017 Aug;23(8):913-914

Calico Life Sciences, South San Francisco, California, USA.

View Article
August 2017

Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.

Mol Cancer Ther 2017 Apr 30;16(4):694-704. Epub 2017 Jan 30.

Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.

View Article
April 2017

Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis.

Cell Metab 2016 Nov 8;24(5):753-761. Epub 2016 Sep 8.

Department of Discovery Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article
November 2016

TORquing metabolic reprogramming in cancer cells.

Cell Cycle 2016 Sep 30;15(18):2387-8. Epub 2016 Jun 30.

b Calico Life Sciences , South San Francisco , CA , USA.

View Article
September 2016

Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.

Nat Commun 2016 Aug 3;7:12351. Epub 2016 Aug 3.

Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, California 94080, USA.

View Article
August 2016

Reproducible pharmacogenomic profiling of cancer cell line panels.

Nature 2016 05;533(7603):333-7

Department of Bioinformatics and Computational Biology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA.

View Article
May 2016

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.

Cancer Cell 2016 Apr 24;29(4):548-562. Epub 2016 Mar 24.

Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080, USA. Electronic address:

View Article
April 2016

Communication in Drug Development: "Translating" Scientific Discovery.

Cell 2016 Mar;164(6):1101-1104

Calico Life Sciences, 1170 Veterans Boulevard, South San Francisco, CA 94080, USA.

View Article
March 2016

Cancer: Bet on drug resistance.

Authors:
Jeff Settleman

Nature 2016 Jan 6;529(7586):289-90. Epub 2016 Jan 6.

Calico Life Sciences, South San Francisco, California 94080, USA.

View Article
January 2016

Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Mol Cancer Res 2015 Apr 9;13(4):713-20. Epub 2015 Feb 9.

Laboratory of Cellular and Molecular Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article
April 2015

Predicting response to HER2 kinase inhibition.

Authors:
Jeff Settleman

Oncotarget 2015 Jan;6(2):588-9

Discovery Oncology, Genentech, Inc., South San Francisco, CA.

View Article
January 2015

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.

Cancer Res 2014 Oct 14;74(20):5878-90. Epub 2014 Aug 14.

Department of Discovery Oncology, Genentech, South San Francisco, California.

View Article
October 2014

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.

Oncotarget 2014 Sep;5(17):7328-41

Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA.

View Article
September 2014

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

Cancer Cell 2014 Aug 24;26(2):207-21. Epub 2014 Jul 24.

Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article
August 2014

Optimizing the treatment of BRAF mutant melanoma.

Authors:
Jeff Settleman

Genome Med 2014 28;6(4):30. Epub 2014 Apr 28.

Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.

View Article
July 2014

From cancer genomics to precision oncology--tissue's still an issue.

Cell 2014 Jun;157(7):1509-14

Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article
June 2014

EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.

Cancer Res 2014 May 19;74(10):2825-34. Epub 2014 Mar 19.

Authors' Affiliations: Department of Radiation Oncology, Massachusetts General Hospital; Center for Cancer Research, Massachusetts General Hospital Cancer Center; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; OncoRay-National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; Institute of Radiation Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden; and Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany

View Article
May 2014

Noncovalent wild-type-sparing inhibitors of EGFR T790M.

Cancer Discov 2013 Feb 10;3(2):168-81. Epub 2012 Dec 10.

Department of Discovery Oncology, Genentech, Inc., South San Francisco, California 94080, USA.

View Article
February 2013

Mechanisms of acquired resistance to targeted cancer therapies.

Future Oncol 2012 Aug;8(8):999-1014

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

View Article
August 2012

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

Curr Opin Genet Dev 2012 Feb 7;22(1):45-9. Epub 2012 Feb 7.

Discovery Oncology, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.

View Article
February 2012

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.

Cell 2012 Feb;148(4):639-50

Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.

View Article
February 2012

Dissecting cancer heterogeneity.

Nat Biotechnol 2011 Dec 8;29(12):1095-6. Epub 2011 Dec 8.

View Article
December 2011

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

Cancer Cell 2011 Aug;20(2):158-72

Massachusetts General Hospital Cancer Center and Harvard Medical School. Building 149, 13th Street, Charlestown, Boston, MA 02129, USA.

View Article
August 2011

Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".

Biochem Pharmacol 2010 Sep 6;80(5):666-73. Epub 2010 Mar 6.

Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article
September 2010

Cancer: miRNA addiction - depending on life's little things.

Curr Biol 2010 Sep;20(18):R812-3

Genentech, South San Francisco, CA 94080, USA.

View Article
September 2010

Discovering tumor suppressor genes through genome-wide copy number analysis.

Curr Genomics 2010 Aug;11(5):297-310

Massachusetts General Hospital Cancer Center and Harvard Medical School, 149, 13th Street, Charlestown, MA 02129, USA.

View Article
August 2010

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

Nat Rev Cancer 2010 Apr 19;10(4):241-53. Epub 2010 Mar 19.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article
April 2010

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

Cancer Res 2010 Feb 2;70(4):1625-34. Epub 2010 Feb 2.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA.

View Article
February 2010

Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Clin Cancer Res 2010 Jan 22;16(1):109-20. Epub 2009 Dec 22.

Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.

View Article
January 2010

Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?

BMC Med 2009 Dec 14;7:78. Epub 2009 Dec 14.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article
December 2009

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

J Clin Oncol 2009 Nov 26;27(33):5650-9. Epub 2009 Oct 26.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.

View Article
November 2009

Targeting the RAF-MEK-ERK pathway in cancer therapy.

Cancer Lett 2009 Oct 12;283(2):125-34. Epub 2009 Feb 12.

Medical Oncology Department and Cancer Research Program, Hospital del Mar-IMIM, Passeig Maritim 25-29, 08003 Barcelona, Spain.

View Article
October 2009

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.

Authors:
Jeff Settleman

Cancer Cell 2009 Oct;16(4):278-9

Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.

View Article
October 2009

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Nat Rev Drug Discov 2009 Sep 24;8(9):709-23. Epub 2009 Jul 24.

Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

View Article
September 2009

Oncogenic K-ras "addiction" and synthetic lethality.

Cell Cycle 2009 Sep 23;8(17):2676-7. Epub 2009 Sep 23.

View Article
September 2009

Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).

Authors:
Jeff Settleman

Semin Oncol 2009 Apr;36(2 Suppl 1):S36-41

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA.

View Article
April 2009

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Clin Cancer Res 2008 Jul;14(13):4079-84

Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA.

View Article
July 2008

Cancer: drivers and passengers.

Nature 2007 Mar;446(7132):145-6

View Article
March 2007

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Nat Genet 2005 Dec 30;37(12):1315-6. Epub 2005 Oct 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA.

View Article
December 2005

p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling.

J Cell Sci 2005 Oct 27;118(Pt 20):4689-700. Epub 2005 Sep 27.

Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Candiolo, Torino 10060, Italy.

View Article
October 2005